02/08/2014 02:41:52 Free Membership Login

Bristol Myers Sqibb News (NYSE:BMY)

DateTimeSource
Headline
07/29/20147:00AMBWEuropean Commission Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) & Pulmonary Embolism (PE), & ...
In the AMPLIFY trial, Eliquis was shown to be non-inferior for the treatment of recurrent venous thromboembolism (VTE)/VTE-related death and was statistically superior in the primary safety endpoint of major bleeding vs. enoxaparin/warfarin In the AMPLIFY-EXT trial, Eliquis demonstrated a superior reduction in VTE/all-cause... More...>>
07/24/20144:01PMPRNUSBioMed Realty And Bristol-Myers Squibb Sign Lease To Expand Relationship To 194,100 Square Feet At Woodside Technology Park I...
BioMed Realty And Bristol-Myers Squibb Sign Lease To Expand Relationship To 194,100 Square Feet At Woodside Technology Park In Redwood City, California Global BioPharmaceutical Leader Leases an Additional 61,000 Square Feet to Grow Its Presence and Research Capabilities in the Bay Area PR Newswire SAN DIEGO, July 24, 2014... More...>>
07/24/201410:11AMDJNBristol-Myers Posts Lower Profit, Revenue -- Update
By Joshua Jamerson Bristol-Myers Squibb Co. reported declines in second-quarter earnings and revenue as the drug maker continues to restructure its operations. Results, though, surpassed analyst expectations, helped by strong sales of the company's cancer drugs. Bristol shares slipped 25 cents to $49.07 in morning trading... More...>>
07/24/20147:30AMBWBristol-Myers Squibb Reports Second Quarter 2014 Financial Results
Posts Second Quarter GAAP EPS of $0.20 and Non-GAAP EPS of $0.48 Achieves Important Regulatory Milestones across Portfolio Approval for Daklinza+Sunvepra Dual Regimen in Japan Positive Advisory Opinions for Daklinza and Eliquis in Europe Plans for Third Quarter Submission of a Biologics License Application in the U.S... More...>>
07/23/20149:00PMBWBristol-Myers Squibb & Ono Pharmaceutical Co., Ltd. Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea & ...
Companies to develop and commercialize Opdivo (nivolumab), Yervoy (ipilimumab), and three early–stage clinical immuno-oncology assets as single agents and combination regimens Bristol-Myers Squibb gains access to Opdivo in Japan, South Korea and Taiwan, broadening company’s leadership in immuno-oncology Ono strengthens... More...>>
07/17/20148:06AMBWBristol-Myers Squibb & Pfizer Announce Enrollment of First Patient in Phase IV EMANATE Trial to Assess Effectiveness & Safety...
Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) today announced that the first patient has been enrolled into a Phase IV clinical trial called EMANATE (Eliquis evaluated in acute cardioversion coMpared to usuAl treatmeNts for AnTicoagulation in subjEcts with NVAF) assessing the effectiveness and safety... More...>>
07/10/201412:36PMBWBristol-Myers Squibb Announces Plans for Third Quarter Submission of a Biologics License Application for Opdivo® (nivolumab)...
Bristol-Myers Squibb Company (NYSE:BMY) today announced that, following discussions with the U.S. Food and Drug Administration (FDA), the company is planning a third quarter submission of a Biologics Licensing Application (BLA) for Opdivo® (nivolumab) for previously treated advanced melanoma. This will mark the second... More...>>
07/10/20147:30AMBWBristol-Myers Squibb Announces Plans for Third Quarter Submission of a Biologics License Application for Opdivo® (nivolumab)...
Bristol-Myers Squibb Company (NYSE:BMS) today announced that, following discussions with the U.S. Food and Drug Administration (FDA), the company is planning a third quarter submission of a Biologics Licensing Application (BLA) for Opdivo® (nivolumab) for previously treated advanced melanoma. This will mark the second... More...>>
07/07/20143:20PMDJNNovartis Wins 'Breakthrough' Status for Leukemia Treatment
ZURICH-- Novartis AG said Monday the U.S. Food and Drug Administration designated a new leukemia treatment it is developing as a "breakthrough" therapy, giving it access to a potentially faster regulatory review process. Basel-based Novartis's CTL019 treatment, which is being tested at the University of Pennsylvania's... More...>>
07/07/20149:00AMDJNU.S. Hot Stocks: Hot Stocks To Watch
Among the companies with shares expected to actively trade in Monday's session are BioDelivery Sciences International Inc. (BDSI), CASI Pharmaceuticals Inc. (CASI) and PetSmart Inc. (PETM). A pain drug developed by Endo Pharmaceuticals PLC and BioDelivery Sciences met its primary endpoint in a Phase 3 study, the companies... More...>>
07/07/20147:00AMBWJapan Approves First All-Oral, Interferon- & Ribavirin-Free Hepatitis C Treatment, Daklinza® (daclatasvir) & Sunvepra® (asu...
Offers new treatment option for genotype 1 HCV patients in Japan who are interferon-ineligible/intolerant, or did not previously respond to treatment Japanese HCV patients in urgent need of care now have opportunity for cure, including older patients and those with compensated cirrhosis Bristol-Myers Squibb Company (NYSE:BMY... More...>>
07/01/201410:11AMBWBristol-Myers Squibb to Announce Results for Second Quarter on July 24
Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the second quarter on Thursday, July 24, 2014. During a conference call at 10:30 a.m. EDT on July 24, company executives will review financial information and will address inquiries from investors and analysts. Investors and the general public are invited... More...>>
06/27/20145:58PMDJNU.S. Hot Stocks: Hot Stocks to Watch
Among the companies with shares expected to actively trade in Friday's session are DuPont Co. (DD), Finish Line Inc. (FINL) and Manitowoc Co. (MTW). Amedisys Inc. (AMED) projected a surprise profit for its second quarter, helped by its cost-cutting plans. Amedisys, a hospice and at-home health-care company, had previously... More...>>
06/27/20147:00AMBWEliquis® (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) & Pulmonary Embolism (PE)...
Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Eliquis (apixaban) be granted marketing authorization for the treatment of DVT (deep vein... More...>>
06/27/20147:00AMBWBristol-Myers Squibb Receives Positive CHMP Opinion for Daklinza® (daclatasvir) for Treatment of Chronic Hepatitis C in the ...
Daklinza in combination with other agents would offer a potential cure for HCV patients with high unmet needs who urgently require treatment, if approved Bristol-Myers Squibb Company (NYSE:BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted... More...>>
06/25/20144:14PMDJNU.S. Hot Stocks: Hot Stocks to Watch
Among the companies with shares expected to actively trade in Wednesday's session are Barnes & Noble Inc. (BKS), Monsanto Co. (MON) and Sequential Brands Group Inc. (SQBG). Barnes & Noble Inc. (BKS) said Wednesday that its board has authorized the company to pursue a split of its retail and Nook businesses into... More...>>
06/24/20146:40PMDJNBristol-Myers Drug Study Halted Early for Benefit
Bristol-Myers Squibb Co. (BMY) said a Phase 3 study of its nivolumab treatment for melanoma was stopped early after an analysis by an independent Data Monitoring Committee showed evidence of superior overall survival compared with another therapy. Nivolumab is designed to target an immune-cell pathway known as PD-1 ("programmed... More...>>
06/24/20146:11PMDJNBristol-Myers Says Study of Melanoma Treatment Shows Favorable Comparison
By Tess Stynes Bristol-Myers Squibb Co. (BMY) said a Phase 3 study of its nivolumab treatment for melanoma was stopped early after an an analysis by an independent Data Monitoring Committee showed evidence of superior overall survival compared with another therapy. Nivolumab is designed to target an immune-cell pathway... More...>>
06/24/20144:45PMBWPhase 3 First-Line Melanoma Study of Nivolumab, an Investigational PD-1 Checkpoint Inhibitor, Demonstrates Superior Overall S...
Bristol-Myers Squibb Company (NYSE:BMY) today announced that a randomized blinded comparative Phase 3 study evaluating nivolumab versus dacarbazine (DTIC) in patients with previously untreated BRAF wild-type advanced melanoma was stopped early because an analysis conducted by the independent Data Monitoring Committee (DMC... More...>>
06/24/20148:00AMBWBristol-Myers Squibb Expands Access to Clinical Trial Data Through Collaboration with Academic Research Institute
Bristol-Myers Squibb (NYSE:BMY) today announced a collaboration with Duke University through its Duke Clinical Research Institute (DCRI) focused on clinical trial transparency. Bristol-Myers Squibb will expand access to a broader set of clinical trial information from in-scope company-sponsored studies and enable an independent... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nyse bmy140802 02:41